Remove Clinical Trials Remove Programs Remove Safety
article thumbnail

Clinical Trial: Cannabinoid Administration Via a Metered-Dose Inhaler Is Safe and Effective for Chronic Pain Patients

NORML

The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Participants inhaled a precise dose containing either THC (at doses of either 0.5mg or 1mg) or placebo. .”

article thumbnail

Wake Network Retains CRO Santé Cannabis to Conduct Clinical Trials in Psilocybin Therapies

Cannabis Law Report

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. . This relationship enables us to initiate our clinical research program and marks an important step for Wake in Canada. ABOUT SANTÉ CANNABIS.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FSD Pharma Inc. Announces Termination of FSD-201 Phase 2 Clinical Trial

Cannabis Law Report

Nasdaq:HUGE) (CSE:HUGE) (FRA:0K9) (the “ Company ” or “ FSD ”) announced today that it intends to terminate the Phase 2 clinical trial of ultra-micronized palmitoylethanolamide (“PEA”), or FSD-201, for use in treating COVID-19. TORONTO–(BUSINESS WIRE)–FSD Pharma Inc.

article thumbnail

Knowde Group Inc.™ Enters Into a Strategic Partnership with LMC Manna Research to Drive Quality and Collaboration in the Conduct of Cannabis and Psychedelic Clinical Trials.

Cannabis Law Report

There is an urgent need for objective, scientifically sound and robust clinical trials to support medicinal cannabis and psychedelics (psilocybin, MDMA, LSD, Ketamine). Extensive early phase experience with appropriate safety oversight and early phase clinic.

article thumbnail

InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial

Puff Puff Post

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

article thumbnail

InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial

Puff Puff Post

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

article thumbnail

Cannabis as a cancer cure: what is the research and where is it going?

The Cannigma

Unlike healthy cells, these abnormal cells don’t die as they are typically programmed to do, and instead begin to grow and divide uncontrollably, effectively circumventing the body’s normal checks and balances. To date, very few human clinical trials have been conducted to assess the effectiveness of THC or CBD in treating cancer.